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Abstract
Introduction—Lymphedema of the arm is a common complication of breast cancer with
symptoms that can persist over long periods of time. For older women (over 50% of breast cancer
cases) it means living with the potential for long-term complications of persistent lymphedema in
conjunction with the common diseases and disabilities of aging over survivorship.
Methods—We identified women ≥65-years diagnosed with primary stage I-IIIA breast cancer.
Data were collected over 7-years of follow-up from consenting patients’ medical records and
telephone interviews. Data collected included self-reported symptoms of persistent lymphedema,
breast cancer characteristics, and selected sociodemographic and health-related characteristics.
Results—The overall prevalence of symptoms of persistent lymphedema was 36% over 7-years
of follow-up. Having stage II or III (OR=1.77, 95%CI 1.07–2.93) breast cancer and having a
BMI>30 (OR=3.04, 95%CI 1.69–5.45) were statistically significantly predictive of symptoms of
persistent lymphedema. Women ≥80-years were less likely to report symptoms of persistent
lymphedema when compared to younger women (OR=0.44, 95%CI 0.18–0.95). Women with
symptoms of persistent lymphedema consistently reported worse general mental health and
physical function.
Conclusion—Symptoms of persistent lymphedema were common in this population of older
breast cancer survivors and had a noticeable effect on both physical function and general mental
health. Our findings provide evidence of the impact of symptoms of persistent lymphedema on the
quality of survivorship of older women. Clinical and research efforts focused on risk factors for
symptoms of persistent lymphedema in older breast cancer survivors may lead to preventative and
therapeutic measures that help maintain their health and well-being over increasing periods of
survivorship.
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INTRODUCTION
Lymphedema of the arm is one of the most common complications of breast cancer with
symptoms that can persist over long periods of time.(1–6) The overall incidence of
lymphedema of the arm (hereafter lymphedema) following breast cancer treatment is
reported to be 26% with a range from 0% to 56% at 2-years post-surgery.(7).(8, 9) Reports
of incidence are inconsistent due to variations by treatment type, time since treatment, and a
lack of uniform diagnostic criteria.(3, 8) According to the American Cancer Society, of the
two million breast cancer survivors in the U.S., approximately 400,000 must cope with
lymphedema on a daily basis.(10) Lymphedema secondary to breast cancer is often
considered benign and not life-threatening, but when symptoms persistent, has been shown
to have long-term physical and psychosocial consequences.(1, 5, 8, 11–20) These include
cosmetic disfiguration, physical discomfort, limited arm movement leading to loss of
functional ability, increased risk of infection, impaired quality of life, and sexual
dysfunction, all of which serve as a constant reminder of the cancer experience.(13, 16, 18,
21–25) Lymphedema is difficult to manage as a chronic condition, and for older women
(over 50% of breast cancer cases)(26) it means living with the potential for long-term
complications of lymphedema in conjunction with the common diseases and disabilities of
aging. The impact of which may be considerable based on the conceptual framework of the
International Classification of Functioning, Disability, and Health.(27)
For these reasons, understanding risk factors for symptoms of persistent lymphedema
(SoPL), specifically in older breast cancer survivors, is of great consequence. Risk factors
for lymphedema in mixed age-group populations include axillary lymph node dissection
(ALND), radiation therapy, age, infection, pre-existing cardiovascular conditions, and
obesity, although their relation to persistence is unclear.(28–35) Moreover, to our
knowledge, no long-term follow-up studies have been conducted to investigate risk factors
of SoPL exclusively among older breast cancer survivors. We addressed this void by
prospectively evaluating the predictors of SoPL in a population of older breast cancer
survivors over 7-years of follow-up. We hypothesized that the set of predictors specific to
SoPL in older survivors would differ from those previously reported in shorter follow-up
mixed age populations and that SoPL would have a negative effect on mental health and
physical function.
MATERIALS AND METHODS
Study Population
The longitudinal study design and subject recruitment procedures have been reported
elsewhere.(36–38) In brief, newly diagnosed breast cancer patients were identified through
regular review of pathology reports at hospitals or collaborating tumor registries in four
geographic regions (Los Angeles, Minnesota; North Carolina, and Rhode Island) with
Institutional Review Board (IRB) approval of the study in each setting. Women were
eligible for the study if: they had stage I disease and a tumor diameter of 1 cm or greater,
stage II-IIIA disease; they were age 65-years or older on the date of diagnosis; and
permission from the attending physician to be contacted for study participation had been
obtained. Additional inclusion criteria included: no prior history of primary breast cancer; no
simultaneously diagnosed or treated second primary tumor at another site; English speaking
and competent for interview with satisfactory hearing. Eligible participants were mailed an
enrollment package and were called by a research staff member from each site who
explained the study’s purpose and participation requirements; potential subjects were given
an opportunity to decline participation and those who verbally agreed to participate were
asked to return a signed consent form approved by the IRB at each site, resulting in a
baseline study population of 660 women. Women who were lost to follow-up before their
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27-month contact or who had insufficient lymphedema data were excluded, leaving 400
women in the analytic study population. Figure 1 shows the study population flow.
Data Collection Procedures
Telephone interviews were conducted at 3 (baseline), 6, 15, 27, 39, 51, 63, 75, and 87-
months after definitive surgery. A definitive surgery-date based on medical record review
was assigned for each subject. Trained interviewers conducted the interviews, which took an
average of 45-minutes to complete, and ascertained sociodemographic information,
psychosocial status, health status, and breast cancer therapies received. Tumor and treatment
information (excepting chemotherapy and tamoxifen use obtained by interview) and
comorbid conditions at the time of diagnosis were collected by medical record review at
least 3-months after the date of definitive surgery.
Analytic Variables
Symptoms of lymphedema—Patient interviews at 15, 27, 39, 51, 75, and 87-months
post definitive surgery assessed lymphedema using a single question that asked “In the past
four weeks, how bothered are you by swelling or lymphedema in either arm?” Subjects
responded on a five-level scale reporting 0=Not at all, 1=a little, 2=a fair amount, 3=much,
or 4=very much (1–4 responses indicating symptoms). SoPL was defined as a positive
response at least two interviews over the follow-up period. Symptoms of transient
lymphedema were categorized as a positive response at 15-month interview but not at any
other follow-up interviews and no positive responses at any interview as having no
symptoms over follow-up.
Sociodemographic characteristics—We classified patient age as 65–69, 70–79, or
80+ years of age; race as white or non-white; education as <high school, high school, or
>high school; marital status as married or not married; having adequate finances to meet
needs (yes/no); employment status as working full/part-time for pay or unemployed; and
health insurance as receiving Medicaid or not.
Breast cancer characteristics—We classified stage as I, II–III, using the TNM
classification.(39) We classified primary tumor therapy as BCS followed by radiation
therapy, BCS alone, or mastectomy. ALND was considered as yes/no as were receipt of
chemotherapy and adjuvant tamoxifen therapy.
Health-related characteristics—We determined the number and type of underlying
diseases present at the time of diagnosis using definitions developed for the Index of Co-
Existent Diseases.(40) A measure of total disease burden as reflected by the presence of as
many as fourteen comorbid conditions was categorized into the following groups: 0, 1–2, 3–
4, or 5 or more. Self-perceived health status before diagnosis was assessed using a single-
item measure “In general, would you say that your health before your breast cancer was
diagnosed was excellent, very good, good, fair or poor?” Self-rated health was dichotomized
as excellent, very good, or good (good) versus fair or poor (poor). Body mass index (BMI)
was derived from the patients’ baseline self-reported weight and height, and was analyzed as
a continuous variable ranging from 18.9–41.7 kg/m anddichotomously as ≤ versus >30. We
asked subjects whether or not they exercised regularly at the 6-month interview. Regular
exercise was defined as some activity for at least one-half hour a day at least three times a
week whose main purpose was to exercise, aside from exercises prescribed by their doctor
or physical therapist specifically for breast cancer. Physical function was assessed by the
Physical Function Index 10 (PFI10, scaled from 0–100, with higher scores indicating better
function) from the Medical Outcomes Study (MOS) SF-36.(41) General mental health was
assessed by the Mental Health Index (MHI5), a 5-item measure of mental health from the
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MOS SF-36 scored on a 0–100 scale (higher scores indicating better mental health).(42)
This scale has been widely used in many populations with chronic disease and cancer; a
score of ≥80 considered good general mental health and an 8-point change clinically
significant.(36, 38, 43–46)
Analytic Strategy
We obtained descriptive statistics (univariate, proportion, frequency) on all study variables.
We then examined the bivariate relations between the independent variables and the
outcome variable using Spearman correlations and chi-square tests. Next, we conducted
analyses comparing continuous variables at each interview time point of subjects with SoPL
to those without using student t-tests. Two variable (crude) and multivariable logistic
regression models were used to evaluate associations between the outcome and the
independent variables. Independent variables demonstrating an association with the outcome
variable we evaluated for potential inclusion in multivariable models. The final subset of
candidate independent variables was selected by the model building strategy described by
Greenland.(47) Subjects with missing data for independent or outcome variables were
excluded from the models. Finally, we conducted lost-to-follow-up analyses by comparing
the baseline population (N=660) to our final analytic population (N=400) using chi-square
and student t-tests. All analyses were performed using SAS version 9.1(48) and all p values
were two-sided.
RESULTS
Characteristics of the Study Population
Sociodemographic, breast cancer, and health-related characteristics of the baseline study
population (N=660) are shown in Table I. Approximately one quarter of the population
came from each of the four study sites. The majority were ≥70-years of age. Most were
white and had a high school education or greater. Just less than half were married and the
majority had adequate finances to meet their needs. Only a small proportion was working
full- or part-time at baseline. About half of the women had stage I disease; the majority
received ALND and either a mastectomy or breast conserving surgery (BCS) followed by
radiation. The majority had two or less comorbid conditions and reported good health. Over
one-half of the women reported exercising regularly at baseline, and 21% had a BMI of ≥30.
On average, these women exhibited high levels of general mental health and physical
function.
We followed 400 women for up to 7-years after definitive surgery (5.8 mean vs. 7.0 median
number of years of follow-up). Table II lists the characteristics of the analytic study
population by symptoms of lymphedema status. The overall prevalence of SoPL was 36%
(145/400), with nearly one-quarter reporting it in all interviews. Only 18 women (4.5%) met
our definition of symptoms of transient lymphedema, limiting statistical comparisons due to
small numbers. Those with symptoms of transient lymphedema were proportionally
younger, more were married and had adequate finances, while fewer received BCS with
radiation or reported good self-rated health before diagnosis. On average they had lower
PFI10 and higher MHI5 scores than women with SoPL.
Baseline Predictors of Symptoms of Persistent Lymphedema
The crude and adjusted results of the logistic regression models for baseline predictors of
SoPL are presented in Table III. Women with stage II–III disease (odds ratio[OR]=1.77,
95% confidence interval[CI] 1.07–2.93), and those having a BMI >30 (OR=3.04, 95%CI
1.69–5.45) at baseline were statistically significantly more likely to report SoPL over
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follow-up. Women 80+ years old were less likely to report SoPL when compared to younger
women (OR=0.44, 95%CI 0.18–0.95).
Symptoms of Persistent Lymphedema, Physical Function and Mental Health over Follow-
up
Figures 2 and 3 show the pattern of physical function (PFI10) and general mental health
(MHI5) scores by SoPL status over the study period. Women with SoPL consistently
reported worse physical function and general mental health over follow-up. There was on
average an 11-point difference (range 6–13 points) in PFI10 scores and a 6-point difference
(range 3–9 points) in MHI5 scores, with statistically significant differences at all interview
time points.
Baseline physical function and general mental health scores did not predict SoPL. Yet,
women with an average 10-point decrease or more in PFI10 and MHI5 scores over follow-
up were more likely to report SoPL (OR=1.97, 95%CI 1.23–3.15; OR=2.53, 95%CI 1.55–
4.12, respectively) when adjusting for other factors. Moreover, in adjusted logistic
regression models comparing women with an average 10-point decrease or more in PFI10
and MHI5 scores over follow-up to those without, persistent lympedema was the single
strongest statistically significant predictor of decreased scores over follow-up
(ORPFI10change=2.32, 95%CI 1.47–3.65; ORMHI5change=2.86, 95%CI 1.78–4.61).
Lost-to-follow-up analysis
Table 1 characteristics of women in the baseline population were compared to those in the
analytic population. There were no statistically significant differences in characteristics
other than mean age and Medicaid; mean age of the baseline population was minimally
higher (73.9±6.0 SD vs. 73.2±5.5 SD, p=0.04) and a higher proportion at baseline reported
having Medicaid (6.2% vs. 3.3%, p=0.04).
DISCUSSION
We determined the prevalence and examined characteristics associated with SoPL in a
longitudinal study of older breast cancer survivors. Over 7-years of follow-up, 36% of breast
cancer survivors reported SoPL and these women consistently reported lower physical
function and general mental health when compared to women without. The odds of
reporting SoPL in the oldest group (80+ years) were lower compared to young old women
(65–69 years). The only statistically significant risk factors identified for SoPL in older
survivors were breast cancer stage and having a BMI>30.
The set of risk factors for SoPL that we identified is not entirely in agreement with that
identified in previous research.(2, 8, 49–51) We found advanced age (80+ years) to be
protective whereas others, with mainly younger mixed-age populations, have found
increasing age to be related to lymphedema risk.(33, 35, 49, 52) In addition, many previous
studies have found ALND to be a strong and significant predictor of lymphedema risk, but
in our study ALND was not statistically significantly related. This may be at least in part due
to the fact that our study, in contrast to others,(4, 8, 49, 53) distinguished between transient
and persistent lymphedema. Additional potential reasons include that previous studies were
conducted when more extensive ALND was being performed and that we had limited study
power (81% of our subjects had ALND). The difference in predictive factors that we found
in comparison to other studies raises questions regarding the relationship among advanced
age, ALND and SoPL.
Since currently no definitive cure for lymphedema exists, prevention by limiting and/or
eliminating risk factors is of prime importance.(49) In the case of the older women in our
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study, only one risk factor (BMI>30) is modifiable. Similar to findings by Werner, Petrek
and others, among more than 15 potential predictive factors, obesity was one of the most
important risk factors for lymphedema.(29–33, 54) Focusing clinical recommendations and
interventions on weight control via dietary and exercise interventions in older breast cancer
survivors may be the most effective preventative and therapeutic measures. Underscoring
this is recent research showing that weight loss achieved by dietary advice to reduce energy
intake reduced breast cancer-related lymphedema significantly.(34) Further research is
needed to evaluate the efficacy of such treatments among older survivors and particularly for
those suffering from persistent versus transient lymphedema.(8) Weight loss and weight
gain prevention can also benefit breast cancer survivors by reducing the risk for earlier
recurrence and poorer survival.(55, 56) Thus, attention to these issues can become part of an
important teachable moment for overweight breast cancer patients as they transition into
follow-up and survivorship care, ensuring that primary care physicians as well as
oncologists understand the detrimental effects of obesity in this patient population.(57–59)
SoPL in this population of older survivors had a noticeable effect on both physical function
and general mental health. It is easy to understand why lymphedema is reported to be one of
the most feared long-term complications of breast cancer treatment.(8) Furthermore, the
interrelationships among lymphedema, physical functional impairment and mental health are
important. Increasing age has been shown in previous research to be a risk factor for both
lymphedema and functional impairment. Functional impairment may be aggravated by
SoPL. In turn, both functional impairment and/or lymphedema, especially over prolonged
periods, may negatively affect mental health, as suggested by the consistently lower general
mental health and physical function scores of the women in this study with SoPL. As
survival continues to improve for older women, mental health issues may take on increasing
importance as does finding effective interventions to prevent and treat their SoPL.
Several limitations of this study should be considered when interpreting our findings. First,
we used a single question to define SoPL based on self-report. This may have caused
misclassification. However, previous studies have demonstrated valid results with similar
self-report measures (5, 9, 60–63) and self-report is most often used in clinical practice.(64,
65) Additionally, since we defined SoPL longitudinally using multiple reports over time, the
effect of misclassification would be expected to be minimized since it is unlikely that
women would mistakenly report lymphedema symptoms or diagnosis over a number of
years. Second, our SoPL question represents a subjective assessment without a non-breast
cancer comparison group that only captures those who were bothered by lymphedema or its
symptoms. There can be a substantial disconnect between prevalence of lymphedema based
on objective diagnostic assessment and being bothered by symptoms. If, in fact, there is a
proportion of women with arm symptoms that are not caused by breast cancer related
lymphedema, as reported in a Canadian study of a younger population(66) then the
prevalence reported here would be overstated. However, the women reporting SoPL in this
study reported symptoms in the same side as their breast cancer surgery, suggesting minimal
misclassification of breast cancer related SoPL. Nonetheless, our use of a subjective
measure also makes our data difficult to compare with other studies. Third, results might
vary by severity and/or type of symptoms, but we were unable to consider differences across
categories of lymphedema severity due to small numbers and question wording. Fourth, the
high attrition rate (260/660) may have affected the validity of our findings. However, the
comparison of baseline and analytic populations on Table 1 characteristics showed minimal
differences. Last, our study population was a largely white, well-educated group of older
women, limiting generalizability to other populations of older breast cancer survivors.
Our findings provide insight into the problem of SoPL in older breast cancer survivors.
However, caution must be used in drawing conclusions about the meaning of the findings;
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further research involving clinically confirmed lymphedema, long-term follow-up, and
larger and more heterogeneous populations is needed. Notwithstanding, this research
provides initial evidence of the impact of SoPL on the quality of long-term survivorship of
older women. Clinical and research efforts focused on risk factors for persistent separate
from transient lymphedema in older breast cancer survivors may lead to preventative and
therapeutic measures that help maintain their health and well-being over increasing periods
of survivorship. Targeting long-term post breast cancer care for high-risk individuals could
help to focus the resources available in clinical practice to those patients most likely to
benefit.
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Figure 1.
Study population flow chart of a 7-year longitudinal study of older breast cancer survivors,
1998–2006.
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Figure 2.
Mean scores with standard deviations of the Physical Function Index for subjects with
symptoms of persistent lymphedema and no symptoms of lymphedema over 7-years of
follow-up
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Figure 3.
Mean scores with standard deviations of the 5-item Mental Health Index for subjects with
symptoms of persistent lymphedema and no symptoms of lymphedema over 7-years of
follow-up
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Table I
Baseline sociodemographic, breast cancer, and health-related characteristics of the baseline population
(N=660) in a 7-year longitudinal study of older breast cancer survivors, 1998–2006
Characteristic at Baseline: N (%)
Sociodemographic:
Enrollment site
 LA 150 (23)
 RI 163 (25)
 MN 188 (28)
 NC 159 (24)
Age
 65–69 years 172 (26)
 70–79 years 372 (56)
 80+ years 116 (18)
Race
 White 620 (94)
 Other 40 (6.1)
Education
 Less than 12 years 115 (17)
 12 years 228 (35)
 More than 12 years 316 (48)
Married 304 (46)
Adequate finances 587 (90)
Employment 65 (10)
Medicaid 40 (6.2)
Breast Cancer:
Stage
 I 336 (51)
 II–III 324 (49)
Therapy
 Mastectomy 333 (50)
 BCS with radiation 265 (40)
 BCS without radiation 52 (7.9)
 Other 10 (1.5)
ALND 532 (81)
SLNB 29 (4.4)
Chemotherapy 145 (22)
Tamoxifen 498 (75)
Health-Related:
Comorbidity – number of conditions
 0 86 (13)
 1–2 340 (52)
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Characteristic at Baseline: N (%)
 3–4 172 (26)
 5 or more 57 (8.7)
Good self-rated health before diagnosis 564 (85)
Exercise regularly 283 (43)
BMI >30 140 (21)
PFI10 (mean ± SD) 79.5 ± 25.1
MHI5 (mean ± SD) 80.7 ± 17.8
LA, Los Angeles, CA; RI, Rhode Island; MN, Minnesota; NC, North Carolina; SD, Standard Deviation; BCS, Breast Conserving Surgery; ALND,
Axillary Lymph Node Dissection; SLNB, Sentinel Lymph Node Biopsy; BMI, Body Mass Index; PFI10, MHI5, 5-item Mental Health Index
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Table II
Sociodemographic, breast cancer, and health-related characteristics of the analytic population (N=400) by
symptoms of lymphedema status in a 7-year longitudinal study of older breast cancer survivors, 1998–2006
Characteristic at Baseline:
No Symptoms of
Lymphedema N=237 N (%)
Symptoms of Persistent
Lymphedema N=145 N (%)
Symptoms of Transient
Lymphedema N=18 N (%)
Sociodemographic:
Enrollment site
 LA 51 (22) 31 (22) 2 (11)
 RI 54 (23) 34 (24) 6 (33)
 MN 71 (29) 41 (28) 4 (22)
 NC 61 (26) 39 (26) 6 (33)
Age
 65–69 years 65 (27) 44 (30) 7 (39)
 70–79 years 134 (57) 90 (62) 10 (56)
 80+ years 38 (16) 11 (7.6) 1 (5.6)
Race
 White 226 (95) 135 (93) 18 (100)
 Other 11 (4.6) 10 (6.9) 0 (0)
Education
 Less than 12 years 32 (14) 29 (20) 3 (17)
 12 years 77 (32) 48 (33) 6 (33)
 More than 12 years 128 (54) 68 (47) 9 (50)
Married 118 (50) 72 (50) 11 (61)
Adequate finances 222 (94) 129 (89) 18 (100)
Employment 23 (9.7) 16 (11) 1 (5.6)
Medicaid 6 (2.6) 6 (4.3) 1 (5.6)
Breast Cancer:
Stage
 I 135 (57) 62 (43) 9 (50)
 II–III 102 (43) 83 (57) 9 (50)
Therapy
 Mastectomy 123 (52) 81 (56) 12 (67)
 BCS with radiation 114 (48) 64 (44) 6 (33)
ALND 193 (81) 128 (88) 15 (83)
Chemotherapy 47 (20) 41 (28) 4 (22)
Tamoxifen 188 (79) 110 (76) 14 (78)
Health-Related:
Comorbidity – number of conditions
 0 35 (15) 16 (11) 3 (17)
 1–2 127 (54) 77 (53) 8 (44)
 3–4 58 (24) 35 (24) 4 (22)
 5 or more 17 (7.2) 17 (12) 3 (17)
Good self-rated health before diagnosis 217 (92) 116 (80) 12 (67)
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Characteristic at Baseline:
No Symptoms of
Lymphedema N=237 N (%)
Symptoms of Persistent
Lymphedema N=145 N (%)
Symptoms of Transient
Lymphedema N=18 N (%)
Exercise regularly 121 (51) 67 (46) 7 (39)
BMI >30 26 (11) 43 (30) 8 (44)
PFI10 (mean ± SD) 83.9 ± 21.3 77.8 ± 25.5 73.2 ± 30.9
MHI5 (mean ± SD) 83.9 ± 14.9 80.1 ± 19.6 84.0 ± 18.8
ALND, Axillary Lymph Node Dissection; LA, Los Angeles, CA; RI, Rhode Island; MN, Minnesota; NC, North Carolina; SD, Standard Deviation;
BCS, Breast Conserving Surgery; BMI, Body Mass Index; PFI10, MHI5, 5-item Mental Health Index
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Table III
Baseline predictors of lymphedema comparing subjects with symptoms of persistent lymphedema (N=145) to
those without symptoms of lymphedema (N=237) in a 7-year longitudinal follow-up study of older breast
cancer survivors, 1998–2006
Characteristic at Baseline: ORcrude (95%CI)* ORadjusted (95%CI)*
Demographic:
Age
 65–69 years 1.0 1.0
 70–79 years 0.99 (0.62–1.58) 1.14 (0.67–1.93)
 80+ years 0.43 (0.20–0.93) 0.44 (0.18–0.95)
Education
 Less than 12 years 1.0 1.0
 12 years 0.69 (0.37–1.28) 0.64 (0.32–1.29)
 More than 12 years 0.59 (0.33–1.05) 0.70 (0.36–1.36)
Adequate finances 0.55 (0.26–1.14) 0.72 (0.32–1.61)
Breast Cancer:
Stage
 I 1.0 1.0
 II or III 1.77 (1.17–2.69) 1.77 (1.07–2.93)
Therapy
 Mastectomy 1.0 1.0
 BCS with radiation 0.85 (0.56–1.29) 1.00 (0.63–1.62)
 BCS without radiation
--
#
--
#
ALND 1.72 (0.94–3.14) 1.43 (0.74–2.79)
Adjuvant therapy
 Chemotherapy 1.59 (0.98–2.58) 1.09 (0.58–2.06)
 Tamoxifen - prescribed 0.82 (0.50–1.34) 0.88 (0.51–1.52)
Health:
Comorbidity number of conditions
 0 1.0 1.0
 1–2 1.33 (0.69–2.56) 1.07 (0.53–2.16)
 3–4 1.32 (0.64–2.73) 1.00 (0.46–2.20)
 5 or more 2.19 (0.89–5.36) 1.21 (0.43–3.40)
BMI >30 3.42 (1.99–5.88) 3.04 (1.69–5.45)
Exercise regularly at 6 months 0.82 (0.54–1.25) 1.11 (0.70–1.76)
PFI10 0.99 (0.98–1.00) 0.99 (0.98–1.00)
MHI5 0.99 (0.98–1.00) 1.00 (0.98–1.01)
OR, odds ratio; CI, confidence interval; BCS, breast conserving surgery; ALND, axillary lymph node dissection; BMI, body mass index; PFI10,
Physical Function Index; MHI5, 5-item Mental Health Index.
*
Model adjusted for all variables listed in table.
#Variable not assessed due to small numbers.
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